NOVARTIS AG-SPONSORED ADR (NVS)
US66987V1098 - ADR
NOVARTIS AG-SPONSORED ADR
NYSE:NVS (12/20/2024, 8:04:00 PM)
After market: 97.11 0 (0%)97.11
+0.34 (+0.35%)
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 76,057 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
NOVARTIS AG-SPONSORED ADR
Lichtstrasse 35
Basel BASEL-STADT CH 4056
P: 41613241111
CEO: Vasant (Vas) Narasimhan
Employees: 76057
Website: https://www.novartis.com/
NVS News
3 days ago - Market News VideoFebruary 2025 Options Now Available For Novartis (NVS)
3 days ago - ChartmillFor those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals.NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
3 days ago - Yahoo FinanceSome 330 jobs hit as Novartis closes Morphosys, WiWo reportsSwiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected. "In November 2024, we made the decision to close the Morphosys sites in Germany and the U.S. by the end of 2025 and to integrate all portfolio activities into Novartis," WiWo cited Novartis as saying. Novartis did not immediately respond to an emailed request for comment from Reuters.
4 days ago - FinancialNewsMediaPromising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal CancersEQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END
4 days ago - FN Media Group LLCPromising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
9 days ago - ChartmillWhy the dividend investor may take a look at NYSE:NVS.Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock.
NVS Twits
Here you can normally see the latest stock twits on NVS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
